Emergent Biosolutions Inc. received a contract modification from the Office of the Assistant Secretary for Preparedness and Response, reducing the minimum purchase dose quantity and increasing the contract value to $1.4 billion. The company also announced its financial and operating results for the three-month period ended March 31, 2024 and will host a conference call to discuss the results.